45.82

2.23% -1.28

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $45.82, with a volume of 457.03K. It is down -2.23% in the last 24 hours and down -11.83% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Previous Close:

$47.10

Open:

$47.65

24h Volume:

457.03K

Relative Volume:

0.80

Market Cap:

$1.76B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-9.875

EPS:

-4.64

Net Cash Flow:

$-123.00M

1W Performance:

+5.69%

1M Performance:

-11.83%

6M Performance:

+38.45%

1Y Performance:

+46.89%

1-Day Range:

$45.54

$48.95

1-Week Range:

$43.32

$49.90

52-Week Range:

$20.08

$57.28

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

323

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	45.73	1.76B	17.39M	-135.89M	-123.00M	-4.64
VRTX Vertex Pharmaceuticals Inc	501.03	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	679.80	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.20	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.18	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

08:23 AM

Tarsus Pharma dips after upsized $125 mln stock offering - TradingView

08:23 AM

04:02 AM

Tarsus Pharmaceuticals Prices Upsized $125 Million Equity Offering -March 13, 2025 at 03:44 am EDT - Marketscreener.com

04:02 AM

02:16 AM

Tarsus prices $125M stock offering - MSN

02:16 AM

Mar 12, 2025

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire

Mar 12, 2025

Tarsus Secures Massive $125M Capital Raise as Investors Rush Into Upsized Offering - StockTitan

Mar 12, 2025

Tarsus Announces Pricing Of Upsized $125 Million Public Offering -March 12, 2025 at 09:50 pm EDT - Marketscreener.com

Mar 12, 2025

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering - GlobeNewswire Inc.

Mar 12, 2025

Tarsus Pharmaceuticals dips on planned $100 million equity raise - TradingView

Mar 12, 2025

Tarsus Pharmaceuticals launches $100 million stock offering By Investing.com - Investing.com Canada

Mar 12, 2025

Tarsus Pharmaceuticals launches $100 million stock offering - Investing.com India

Mar 12, 2025

Tarsus Announces Proposed $100.0 Million Public Offering - GlobeNewswire

Mar 12, 2025

Tarsus Unveils Major $100M Public Offering with Goldman Sachs Leading - StockTitan

Mar 12, 2025

Tarsus Pharmaceuticals’ SWOT analysis: specialty pharma stock faces growth hurdles - Investing.com

Mar 12, 2025

Mar 11, 2025

Tarsus Pharma: Strong Execution In Xdemvy Commercialization (NASDAQ:TARS) - Seeking Alpha

Mar 11, 2025

Mar 10, 2025

Oppenheimer & Co. Inc. Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World

Mar 10, 2025

Mar 09, 2025

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Buy” by Brokerages - Defense World

Mar 09, 2025

Mar 08, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - Defense World

Mar 08, 2025

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% Following Analyst Upgrade - Defense World

Mar 08, 2025

Mar 07, 2025

Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & Tarsus Pharmaceuticals (NASDAQ:TARS) - Defense World

Mar 07, 2025

Mar 06, 2025

Tarsus to Participate in Upcoming Investor Conference - GlobeNewswire

Mar 06, 2025